Octagon Capital Advisors LP 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Octagon Capital Advisors LP disclosed 26 US equity positions worth $640.6m in its Q3 2025 13F filing. The largest position was ABVX at 17.6% of the reported book, followed by DNTH and GOSS. Against the Q2 2025 filing, it opened 4 new positions, added to 7 and reduced 8 among the top 26 holdings.
What did Octagon Capital Advisors LP own in Q3 2025? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | 17.6% | $112.5m | 1,325,000 | 5% | added | |
| 2 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 14.8% | $95.1m | 2,416,667 | 3% | added |
| 3 | GOSS GOSSAMER BIO INC | Healthcare | 7.0% | $44.8m | 17,050,000 | -7% | reduced |
| 4 | COGT COGENT BIOSCIENCES INC | Healthcare | 6.4% | $41.3m | 2,874,111 | 4% | added |
| 5 | AVBP ARRIVENT BIOPHARMA INC | 5.7% | $36.4m | 1,971,054 | 1% | added | |
| 6 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 4.8% | $30.7m | 2,624,000 | 8% | added |
| 7 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 4.6% | $29.7m | 9,067,500 | -28% | reduced |
| 8 | MERUS N V | 4.5% | $29.0m | 308,000 | -21% | reduced | |
| 9 | TRVI TREVI THERAPEUTICS INC | Healthcare | 4.0% | $25.8m | 2,815,000 | -23% | reduced |
| 10 | BRD1EUR MIND MEDICINE MINDMED INC | 3.9% | $25.1m | 2,130,000 | 0% | held | |
| 11 | APLSUSD APELLIS PHARMACEUTICALS INC | 3.2% | $20.4m | 903,500 | 0% | held | |
| 12 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 3.2% | $20.4m | 360,000 | 35% | added |
| 13 | CNTA CENTESSA PHARMACEUTICALS PLC | 3.1% | $20.1m | 830,000 | -19% | reduced | |
| 14 | PHVS PHARVARIS N V | 2.8% | $18.0m | 722,595 | 7% | added | |
| 15 | 4XC1 KALVISTA PHARMACEUTICALS INC | 2.4% | $15.5m | 1,273,333 | 0% | held | |
| 16 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 2.2% | $14.1m | 1,115,000 | 0% | held |
| 17 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 1.9% | $12.1m | 1,043,110 | – | new | |
| 18 | DBVT DBV TECHNOLOGIES S A | 1.6% | $10.2m | 1,018,021 | 0% | held | |
| 19 | NUVB NUVATION BIO INC | Healthcare | 1.5% | $9.7m | 2,633,334 | -66% | reduced |
| 20 | CDTX CIDARA THERAPEUTICS INC | 1.5% | $9.6m | 100,000 | – | new | |
| 21 | MAZE MAZE THERAPEUTICS INC | 0.7% | $4.6m | 177,667 | 0% | held | |
| 22 | NGNE NEUROGENE INC | 0.7% | $4.4m | 252,000 | -17% | reduced | |
| 23 | UNCY UNICYCIVE THERAPEUTICS INC | 0.7% | $4.4m | 1,000,000 | 0% | held | |
| 24 | PEPG PEPGEN INC | Healthcare | 0.5% | $3.2m | 700,000 | – | new |
| 25 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.5% | $3.2m | 115,000 | – | new |
| 26 | NUVATION BIO INC | 0.1% | $385.2k | 104,112 | -32% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.